Voyager Secures Mission Management Role for Exobiosphere’s First Automated Drug Screening Campaign in Orbit

Voyager Technologies and Exobiosphere have signed a new mission management contract that will bring a fully automated drug screening platform to the International Space Station. The agreement represents another step in expanding commercial research capabilities in microgravity, an area of growing interest for aerospace organizations seeking to diversify on‑orbit applications and strengthen the business case for future commercial stations.

Advancing Commercial Access to Microgravity Research

Voyager will serve as mission integrator for Exobiosphere’s Orbital High Throughput Screener, a compact payload designed to automate biological experiments at scale. The company will oversee project management, safety and verification to NASA standards, ISS integration, and coordination of on‑orbit operations. This type of mission support continues to be a core component of Voyager’s strategy to broaden access to low Earth orbit for government, academic, and commercial partners.

Building a Higher Cadence for On‑Orbit Life Sciences

Exobiosphere’s platform is engineered for repeat use, allowing samples and consumables to be swapped between campaigns without redeploying hardware. The company expects this approach to increase experiment cadence and reduce barriers for pharmaceutical and biotech customers that are beginning to explore microgravity as a tool for drug discovery. The OHTS payload is capable of running more than 2,000 simultaneous screening samples with integrated microscopy, luminescence reading, and autonomous reagent exchange, positioning it as one of the more advanced life‑science systems currently headed to station.

Strengthening Europe’s Role in Low Earth Orbit Operations

Voyager Technologies Europe will lead the integration effort, reflecting the company’s intent to expand its operational footprint across the region. The team continues to support European partners preparing for the transition from the ISS to next‑generation commercial stations, including Starlab. The contract reinforces Voyager’s broader objective of enabling a sustainable commercial LEO ecosystem by helping organizations translate research concepts into operational missions.

Implications for Aerospace Stakeholders

For aerospace readers, the agreement highlights the increasing intersection between space infrastructure and non‑traditional commercial sectors. Automated biological research is emerging as a promising use case for both current and future orbital platforms, offering new revenue streams and operational demand that can support long‑term station viability. As companies like Voyager and Exobiosphere build repeatable mission architectures, they contribute to the growing market foundation required for commercial LEO to mature.